Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia

Phase 4RecruitingNCT06624696

Sun Yat-sen University204 enrolled

Overview

This randomized controlled study is to evaluate the effectiveness of inhaling penehyclidine hydrochloride in reducing perioperative respiratory adverse events in children at risk undergoing minor elective surgery.

Children with high risk factors of perioperative respiratory adverse events (PRAEs) remains a challenge for general anesthesia, inhalation of penehyclidine hydrochloride (PHC) has been showed to reduce postoperative pulmonary complications and enhance the recovery in high-risk surgical patients. Thus, prophylactic PHC inhalation might show promising benefits against PRAEs in pediatric anesthesia. This clinical study is designed to test the hypothesis that pediatric patients who exist at least 1 risk factor of PRAEs prophylactically to inhale PHC have a lower prevalence of PRAEs.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

204

Conditions

Respiratory Hypersensitivity Perioperative Respiratory Adverse Events Anticholinergics

Interventions

Penehyclidine hydrochlorideDRUG

The penehyclidine hydrochloride will be diluted to a total volume of 5 mL with normal saline, added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.

Normal SalineDRUG

The normal saline with a total volume of 5 mL will be added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.

Eligibility

Sex: ALLMin age: 3 YearsMax age: 7 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Pediatric patients aged 3 to 7 years. 2. Scheduled to undergo ophthalmic surgery. 3. Judged to be at risk of PRAEs (with at least one parentally reported risk factor for the PRAEs, including history of a recent cold, wheezing during exercise, wheezing more than three times in the past 12 months, nocturnal dry cough, eczema, or a family history of asthma, rhinitis, eczema, or exposure to passive smoke). Exclusion Criteria: 1. American Society of Anesthesiologists (ASA) physical classification ≥ IV. 2. Known cardiopulmonary diseases (eg. uncorrected congenital heart disease, primary or secondary pulmonary hypertension, tumors, or structural lung diseases). 3. Severe renal dysfunction (requirement of renal replacement therapy) or severe hepatic dysfunction (Child-Pugh grade C); 4. Neurological disorders. 5. Neuromuscular diseases. 6. Contraindication for PHC. 7. Inhalation of β2-receptor activator, M-receptor blockers and/or glucocorticoids within 1 month before surgery. 8. Allergy to anticholinergic drugs. 9. Use of endotracheal tube (ETT) for ventilation. 10. Known difficult airway. 11. Severe upper respiratory tract infections (URTIs) and the anesthesiologist recommended delaying surgery. 12. Participation in other clinical trial during the last month or within the six half-life periods of the study drug used in the last trial. 13. Parents refusing to allow their children to participate. 14. Obesity, with a body mass index (BMI) over 95th percentile according to the WHO guideline.

Locations (2)

Zhongshan Ophthalmic Center, Sun Yat-sen University

Guangzhou, Guangdong, China

RECRUITING

Shenzhen Eye Hospital

Shenzhen, Guangdong, China

NOT_YET_RECRUITING

Outcomes

Primary Outcomes

The incidence of PRAEs

PRAEs are subdivided into two types: major (bronchospasm and laryngospasm) and minor (severe coughing, breath holding, desaturation, upper airway obstruction, and stridor) events. The primary outcome is the incidence of PRAEs. Patients will be considered positive for respiratory adverse events if at least 1 of the above adverse events occurs.

Time frame: From beginning of anesthesia induction until the completion of postoperative recovery in PACU (including the phases of anesthesia induction, anesthesia maintenance, postoperative emergency and postoperative recovery), assessed up to 24 hours.

Secondary Outcomes

The severity of major respiratory adverse events if occurs

Major respiratory adverse events include laryngospasm and bronchospasm. Laryngospasm will be scored according to its severity as follows: 1=none, 2=partial-reposition airway, 3=partial-continuous positive airway pressure (CPAP), 4=complete-muscle relaxant. Bronchospasm will be scored according to its severity as follows: 1=none, 2= expiration only, 3= expiration and inspiration, 4=difficult to ventilate, require treatment.

Ease of LMA insertion

This outcome includes time to successful insertion, the number of insertion attempts, and difficulty at insertion.

Time frame: From the beginning of LMA insertion until the completion of successful LMA insertion, assessed up to 24 hours

The episode and degree of salivation during removal of LMA

Degree of salivation is evaluated as follows: 1=none; 2=minimal, no suction; 3=moderate, suction 1×; 4=copious, suction\>1×.

Time frame: At the time of LMA removal, assessed up to 24 hours

The airway hyperreactivity score

This score is used to assessed severity of PRAEs, accounting for the intensity of coughing, breath holding, and oxygen desaturation on a scale ranging from 0 (none) to 4 (severe). The maximum score is 12, and a score of ≤3 is categorized as mild, 4 to 8 as moderate, and ≥9 as severe.

Time frame: From the time of LMA removal until regaining consciousness from anesthesia, assessed up to 24 hours

The anesthesia-related time

The anesthesia-related time includes time to LMA removal, and PACU stay time.

Time frame: During the phases of anesthesia emergence and recovery, assessed up to 24 hours

Emergence agitation

Emergence agitation will be evaluated within stay in PACU using the Aono's four point scale (1: calm; 2: not calm but easily consolable; 3: not easily calmed restless or moderately agitated; 4: combative, disoriented, or excited). The scale scoring of 1 and 2 are considered as the absence of EA, and scale of 3 and 4 are considered as the presence of EA.

Time frame: From the time of LMA removal until regaining consciousness from anesthesia, assessed up to 24 hours

Postoperative pain score

Postoperative pain score will be assessed within stay in the PACU using the Wong-Baker Pain Scale. A score higher than 4 is defined as moderate-to-severe pain which need to be timely managed.

Time frame: From the time of arrival in PACU until the time of discharge from PACU, assessed up to 24 hours

The change of systolic blood pressure (SBP)

The changes of SBP will be recorded.

Time frame: At baseline; 5 minutes after inhaling PHC; the completion of inhaling PHC; LMA insertion; upon arrival in PACU; pre-LMA mask removal; post-LMA mask removal; ready to discharge from PACU, assessed up to 24 hours

The change of heart rate (HR)

The changes of HR will be recorded.

The change of SpO2

The change of SpO2 will be recorded.

Other adverse events

Other adverse events potentially related to inhale the study drug from beginning of inhalation until the 24 postoperative hours, including postoperative nausea and vomitting (PONV), dry month, palpation, dizziness, fever, cough, urine retention, and flushing.

Time frame: From beginning of inhalation until the 24 postoperative hours.

The incidence of respiratory infections within 7 days after surgery

Children who develop respiratory infections within 7 days after surgery will be recorded during postoperative follow-up.

Time frame: Within 7 days after surgery.